Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)

Hillerod Hospital, Denmark

Status and phase: Terminated; Phase 4

Conditions: Major Depression

Treatments: Drug: escitalopram; Drug: nortriptyline

Study type: Interventional

Funder types: Other

Identifiers

NCT00660062

DUAG-7

Details and patient eligibility

About

The main purpose of this study is to investigate the relapse preventing efficacy of escitalopram in a dose range and nortriptylin in a single dose in patients having been treated successfully with a course of electroconvulsive treatment (ECT).

Full description

This study records severity of depression and relapse in patients treated for a major depressive disorder with electroconvulsive treatment (ECT)in a period og 6 month after end of ECT treatment. Patients will be randomized into four groups treated with escitalopram 10 mg, 20 mg, 30 mg or nortriptylin 100 mg daily dosages. The primary outcome measure is relapse and secondary outcome measure is tolerability.

The study is a multicenter trial within Denmark.

Enrollment: 47 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Remission from a major depressive episode after ECT treatment

Exclusion criteria

• Suicidality (Hamilton item 3 score of 3 or more)
• Symptoms mania (MAS score of 15 or more)
• Duration of actual depressive episode more than 2 years
• Compulsory measures of any kind
• Dementia
• Severe somatic illness
• Pregnant or lactating subject
• Known clinical relevant malabsorption.
• Epilepsia
• Clinically substantial cognitive deterioration due to ECT treatment
• schizophrenia, schizopreniform or schizo-affective disorder
• Bipolar I, Bipolar II eller
• Rapid cycling bipolar disorder
• Abuse of alcohol or drugs
• Early relapse (less than 2 month) after ECT
• Inadequate contraception
• Known intolerance to any of the used study medications
• Myocardial infarction in the last 6 month
• Clinical important liver disease
• Any known disturbance of the cardiac conduction system, cardiac insufficiency,or other clinical important cardiac disease
• Treatment with a MAO-inhibitor
• Treatment with norepinephrine or epinephrine
• Known hyperthyroidism or treatment with thyroid hormones
• Known ortostatic hypertension.
• Glaucoma
• Known hereditary galactoseintolerance, Lapp Lactase deficiency) or gluco-se/galactosemalabsorption.
• Ongoing treatment with sympatomimetica efedrine, isoprenaline, physostigmine, dopamine, levodopa, phenylephrine.
• Ongoing treatment with anticholinergica, antiparkinson treatment, antihistamines, atropine, biperiden,
• Ongoing treatment with drugs that prolongs the cardiac QT-interval, such as quinidine, antihistamines, terfenadine og sotalole
• Ongoing treatment with fluconazole or terbinafine
• Ongoing treatment with mefloquin.
• Known intolerance to escitalopram
• Ongoing treatment with serotonergic acting substances such as tramadole, sumatriptane

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

47 participants in 4 patient groups

Escitalopram 10 mg daily

Experimental group

Description:

Escitalopram 10 mg daily

Treatment:

Drug: escitalopram

Drug: escitalopram

Drug: escitalopram

Escitalopram 20 mg daily

Experimental group

Description:

Escitalopram 20 mg daily

Treatment:

Drug: escitalopram

Drug: escitalopram

Drug: escitalopram

escitalopram 30 mg daily

Experimental group

Description:

escitalopram 30 mg daily

Treatment:

Drug: escitalopram

Drug: escitalopram

Drug: escitalopram

Nortriptylin 100 mg daily

Active Comparator group

Description:

Nortriptylin 100 mg daily

Treatment:

Drug: nortriptyline